Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19
The global pandemic of novel coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has created an urgent need for effective antivirals. Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical...
Gespeichert in:
| Veröffentlicht in: | Pharmacotherapy 2020-07, Vol.40 (7), p.659-671 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 671 |
|---|---|
| container_issue | 7 |
| container_start_page | 659 |
| container_title | Pharmacotherapy |
| container_volume | 40 |
| creator | Jorgensen, Sarah C.J. Kebriaei, Razieh Dresser, Linda D. |
| description | The global pandemic of novel coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has created an urgent need for effective antivirals. Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre‐clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic β‐coronaviruses, including SARS‐CoV‐2. In this article, we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics, and in vitro activity against coronaviruses as well as clinical experience and current progress in COVID‐19 clinical trials. |
| doi_str_mv | 10.1002/phar.2429 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7283864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2424852907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5099-d3f5b384499927c43d14f1aeacc06c97c063524c7ecfb2e692d60fabd8449f3b3</originalsourceid><addsrcrecordid>eNp1kc1OGzEURq2qVRNoF30BZKkrJAZsj2c8ZoGEQihISERR263l8VwnRjPj4EkC2fEIPCNPgtP8qF10Yy_u-Y6v_CH0jZJTSgg7m011OGWcyQ-oTwuRJZJS_hH1CRMiIYQUPXTQdQ8RpTlnn1EvZZznrBB9NB1DU0Hnli6c4zEsHTxhb_EoGhttfO0nqxM8CvD28mpq1zqja3yl5_oE67bCwwbCxLUTPNjNhs8zCA5aA9j6gAf3v2-vYpbKL-iT1XUHX7f3Ifp1Pfw5uEnu7n_cDi7vEpMRKZMqtVmZFpxLKZkwPK0ot1SDNobkRop4phnjRoCxJYNcsionVpfVOmLTMj1EFxvvbFE2UBlo50HXahZco8NKee3Uv5PWTdXEL5VgRVrkPAq-bwXBPy6gm6sHvwht3FnFL-ZFxiQRkTreUCb4rgtg9y9QotalqHUp64SM7NHfK-3JXQsRONsAT66G1f9NanRzOf6jfAdQkZkn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424852907</pqid></control><display><type>article</type><title>Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Jorgensen, Sarah C.J. ; Kebriaei, Razieh ; Dresser, Linda D.</creator><creatorcontrib>Jorgensen, Sarah C.J. ; Kebriaei, Razieh ; Dresser, Linda D.</creatorcontrib><description>The global pandemic of novel coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has created an urgent need for effective antivirals. Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre‐clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic β‐coronaviruses, including SARS‐CoV‐2. In this article, we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics, and in vitro activity against coronaviruses as well as clinical experience and current progress in COVID‐19 clinical trials.</description><identifier>ISSN: 0277-0008</identifier><identifier>EISSN: 1875-9114</identifier><identifier>DOI: 10.1002/phar.2429</identifier><identifier>PMID: 32446287</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antiviral activity ; Antiviral agents ; Antiviral drugs ; Clinical trials ; Coronaviridae ; coronavirus ; Coronaviruses ; COVID-19 ; GS‐5734 ; Metabolites ; Nucleoside analogs ; Pandemics ; Pharmacokinetics ; Proofreading ; Remdesivir ; Review Of Therapeutics ; Reviews of Therapeutics ; SARS‐CoV‐2 ; severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Transcription ; Zoonoses</subject><ispartof>Pharmacotherapy, 2020-07, Vol.40 (7), p.659-671</ispartof><rights>2020 Pharmacotherapy Publications, Inc.</rights><rights>This article is protected by copyright. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5099-d3f5b384499927c43d14f1aeacc06c97c063524c7ecfb2e692d60fabd8449f3b3</citedby><cites>FETCH-LOGICAL-c5099-d3f5b384499927c43d14f1aeacc06c97c063524c7ecfb2e692d60fabd8449f3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fphar.2429$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fphar.2429$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,777,781,882,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32446287$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jorgensen, Sarah C.J.</creatorcontrib><creatorcontrib>Kebriaei, Razieh</creatorcontrib><creatorcontrib>Dresser, Linda D.</creatorcontrib><title>Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19</title><title>Pharmacotherapy</title><addtitle>Pharmacotherapy</addtitle><description>The global pandemic of novel coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has created an urgent need for effective antivirals. Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre‐clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic β‐coronaviruses, including SARS‐CoV‐2. In this article, we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics, and in vitro activity against coronaviruses as well as clinical experience and current progress in COVID‐19 clinical trials.</description><subject>Antiviral activity</subject><subject>Antiviral agents</subject><subject>Antiviral drugs</subject><subject>Clinical trials</subject><subject>Coronaviridae</subject><subject>coronavirus</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>GS‐5734</subject><subject>Metabolites</subject><subject>Nucleoside analogs</subject><subject>Pandemics</subject><subject>Pharmacokinetics</subject><subject>Proofreading</subject><subject>Remdesivir</subject><subject>Review Of Therapeutics</subject><subject>Reviews of Therapeutics</subject><subject>SARS‐CoV‐2</subject><subject>severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Transcription</subject><subject>Zoonoses</subject><issn>0277-0008</issn><issn>1875-9114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kc1OGzEURq2qVRNoF30BZKkrJAZsj2c8ZoGEQihISERR263l8VwnRjPj4EkC2fEIPCNPgtP8qF10Yy_u-Y6v_CH0jZJTSgg7m011OGWcyQ-oTwuRJZJS_hH1CRMiIYQUPXTQdQ8RpTlnn1EvZZznrBB9NB1DU0Hnli6c4zEsHTxhb_EoGhttfO0nqxM8CvD28mpq1zqja3yl5_oE67bCwwbCxLUTPNjNhs8zCA5aA9j6gAf3v2-vYpbKL-iT1XUHX7f3Ifp1Pfw5uEnu7n_cDi7vEpMRKZMqtVmZFpxLKZkwPK0ot1SDNobkRop4phnjRoCxJYNcsionVpfVOmLTMj1EFxvvbFE2UBlo50HXahZco8NKee3Uv5PWTdXEL5VgRVrkPAq-bwXBPy6gm6sHvwht3FnFL-ZFxiQRkTreUCb4rgtg9y9QotalqHUp64SM7NHfK-3JXQsRONsAT66G1f9NanRzOf6jfAdQkZkn</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Jorgensen, Sarah C.J.</creator><creator>Kebriaei, Razieh</creator><creator>Dresser, Linda D.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>5PM</scope></search><sort><creationdate>202007</creationdate><title>Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19</title><author>Jorgensen, Sarah C.J. ; Kebriaei, Razieh ; Dresser, Linda D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5099-d3f5b384499927c43d14f1aeacc06c97c063524c7ecfb2e692d60fabd8449f3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiviral activity</topic><topic>Antiviral agents</topic><topic>Antiviral drugs</topic><topic>Clinical trials</topic><topic>Coronaviridae</topic><topic>coronavirus</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>GS‐5734</topic><topic>Metabolites</topic><topic>Nucleoside analogs</topic><topic>Pandemics</topic><topic>Pharmacokinetics</topic><topic>Proofreading</topic><topic>Remdesivir</topic><topic>Review Of Therapeutics</topic><topic>Reviews of Therapeutics</topic><topic>SARS‐CoV‐2</topic><topic>severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Transcription</topic><topic>Zoonoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jorgensen, Sarah C.J.</creatorcontrib><creatorcontrib>Kebriaei, Razieh</creatorcontrib><creatorcontrib>Dresser, Linda D.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jorgensen, Sarah C.J.</au><au>Kebriaei, Razieh</au><au>Dresser, Linda D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19</atitle><jtitle>Pharmacotherapy</jtitle><addtitle>Pharmacotherapy</addtitle><date>2020-07</date><risdate>2020</risdate><volume>40</volume><issue>7</issue><spage>659</spage><epage>671</epage><pages>659-671</pages><issn>0277-0008</issn><eissn>1875-9114</eissn><abstract>The global pandemic of novel coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has created an urgent need for effective antivirals. Remdesivir (formerly GS‐5734) is a nucleoside analogue pro‐drug currently being evaluated in COVID‐19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre‐clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic β‐coronaviruses, including SARS‐CoV‐2. In this article, we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics, and in vitro activity against coronaviruses as well as clinical experience and current progress in COVID‐19 clinical trials.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32446287</pmid><doi>10.1002/phar.2429</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-0008 |
| ispartof | Pharmacotherapy, 2020-07, Vol.40 (7), p.659-671 |
| issn | 0277-0008 1875-9114 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7283864 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Antiviral activity Antiviral agents Antiviral drugs Clinical trials Coronaviridae coronavirus Coronaviruses COVID-19 GS‐5734 Metabolites Nucleoside analogs Pandemics Pharmacokinetics Proofreading Remdesivir Review Of Therapeutics Reviews of Therapeutics SARS‐CoV‐2 severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Transcription Zoonoses |
| title | Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A37%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Remdesivir:%20Review%20of%20Pharmacology,%20Pre%E2%80%90clinical%20Data,%20and%20Emerging%20Clinical%20Experience%20for%20COVID%E2%80%9019&rft.jtitle=Pharmacotherapy&rft.au=Jorgensen,%20Sarah%20C.J.&rft.date=2020-07&rft.volume=40&rft.issue=7&rft.spage=659&rft.epage=671&rft.pages=659-671&rft.issn=0277-0008&rft.eissn=1875-9114&rft_id=info:doi/10.1002/phar.2429&rft_dat=%3Cproquest_pubme%3E2424852907%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2424852907&rft_id=info:pmid/32446287&rfr_iscdi=true |